Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
about
A Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal CancerEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesEGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.Time-dependent endpoints as predictors of overall survival in multiple myelomaJoint modeling tumor burden and time to event data in oncology trials.Endpoints in phase II trials for advanced non-small cell lung cancer.Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsCorrelating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study.MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Initial partial response and stable disease according to RECIST indicate similar survival for chemotherapeutical patients with advanced non-small cell lung cancerRecurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic reviewEfficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.Detecting an overall survival benefit that is derived from progression-free survivalHigh expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure.Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trialsIdentification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end pointsOxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer.Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial.Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trialsA Weibull multi-state model for the dependence of progression-free survival and overall survival.Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effectsPathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.Progression-free survival as a surrogate endpoint in advanced breast cancerUnderstanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancerImmunotherapy in prostate cancer: emerging strategies against a formidable foe.Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer.Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancerRecurrent head and neck cancer: current treatment and future prospects.Treatment in advanced colorectal cancer: what, when and how?Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.New evidence-based adaptive clinical trial methods for optimally integrating predictive biomarkers into oncology clinical development programs.
P2860
Q26782245-312F5BCE-1B85-47BA-8C5F-5190F19C9128Q26786618-B1851C5E-DB1C-4CBF-A293-C7C8B265C2B5Q26797292-91D4EFE9-F024-4257-9C30-3A8D09BADF92Q27008070-8D9E62CC-2C74-421B-B0D1-E1B01038C0D4Q27851583-8F3A40DF-367A-43F0-8EF6-55B754A615BCQ30538040-2F79CB38-3F51-4BC4-A9EE-815BA2243CF7Q30837595-02D21324-9630-4242-9897-4F22521810E2Q33557040-C640E08B-F00C-4FCA-BC95-991F77B9362CQ33600372-80C6176B-C03C-4018-9433-A94F0C527A16Q33733088-A3BA8565-B067-4016-B191-56F743E8E8A2Q33738954-8BEF403B-C1FF-4531-8D76-03B05BB91330Q33771180-09B83EC5-EE61-455D-9B3F-5F2CB630731CQ33779885-4E18FE94-2F4D-4882-B7E4-F64725F80E41Q33849656-C724A87D-77E5-42CA-99D7-E1DA5DD69FDFQ33927755-BAC18F8B-2586-4525-A196-89DBB527F8A2Q34063143-2B5990FE-C402-4719-896F-116B90A4A7BBQ34178509-2D5D6D7C-0DBE-4C30-8C6E-1B2584C85C3EQ34463636-5C17927B-5DDC-48B4-8A21-A8BC24940622Q34716556-0E8D9138-083D-4A26-A728-BE11126DC661Q35004750-47518479-BD6D-4AEF-917B-23B158CDDDC2Q35088086-6834ECB5-C364-43C3-B762-8ECCE826BB28Q35223631-548C3866-CB3C-428A-A8F1-660DC4079AE7Q35584926-9DCFF809-9072-4294-80D9-C03C5E23D9BBQ35623301-CF71E110-3682-4123-B9D6-03B9851D3372Q35645254-075EACC6-2F00-42CB-814B-B21F48EE75BCQ35812284-AADD42AF-68EF-4998-8CC5-10A1D7293275Q35825822-5524E636-32E8-43F4-96F8-13BC6897E1CDQ36202850-9A965142-D4BE-4212-BFDC-66ACE7F989ABQ36303649-4977DE12-AB48-451F-9623-1144CEFE67E1Q36349459-C4C03A00-8070-4120-829E-9BC4B8D8F28EQ36405660-22064617-E1EA-42AB-BF98-333D2ECD6B28Q36552307-6CA51A15-290A-46CC-B8B9-AD97F033FBB0Q36706109-D8F6C15A-8359-4322-B75C-4CBBB2D7A58CQ36708792-0329DFDB-C401-4E8C-9E4A-57A24C957E6CQ36977501-FB6E096A-68CC-4079-A0DF-7D4CE5C74439Q37094989-E64EE764-64B1-4807-B79D-165305561402Q37118936-B585B311-E624-4ACC-AA22-9A8350C471AFQ37225720-6A7652EF-3589-4BED-900B-DAC33B6B3AD8Q37275076-7A1A9321-32DA-4366-9D31-35C5940F3039Q37353962-779CDFB3-5810-4AB5-AD0D-12686B9C3F4C
P2860
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Surrogate end points for media ...... ls of first-line chemotherapy.
@en
type
label
Surrogate end points for media ...... ls of first-line chemotherapy.
@en
prefLabel
Surrogate end points for media ...... ls of first-line chemotherapy.
@en
P2093
P356
P1476
Surrogate end points for media ...... als of first-line chemotherapy
@en
P2093
Eric X Chen
Lillian L Siu
Patricia A Tang
P304
P356
10.1200/JCO.2006.08.1935
P407
P577
2007-09-17T00:00:00Z